Dicerna Pharmaceuticals reported $62.95M in Sales Revenues for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Sales Change
Acceleron Pharma XLRN:US $ 34.2M 6.26M
Agenus AGEN:US $ 252.95M 242.22M
Alnylam Pharmaceuticals ALNY:US $ 187.63M 32.92M
Amgen AMGN:US $ 6706M 180M
Arrowhead Research ARWR:US $ 38.28M 7.61M
Biogen BIIB:US $ 2778.9M 3.9M
Bluebird Bio BLUE:US $ 22.68M 15.2M
Dicerna Pharmaceuticals DRNA:US $ 62.95M 21.62M
Exelixis EXEL:US $ 328.42M 56.75M
Gilead Sciences GILD:US $ 7421M 1204M
GlaxoSmithKline GSK:LN 9077M 985M
Immunogen IMGN:US $ 9.21M 7.74M
Intercept Pharmaceuticals ICPT:US $ 92.83M 3.75M
Intrexon XON:US $ 21.56M 12.02M
IONIS PHARMACEUT IONS:US $ 133M 7.25M
Karyopharm Therapeutics KPTI:US $ 37.69M 15.09M
Lexicon Pharmaceuticals LXRX:US $ 0.02M 0.21M
Macrogenics MGNX:US $ 15.66M 15.1M
Merk MRK:US $ 13154M 1752M
Mirati Therapeutics MRTX:US $ 71.79M 71.79M
Pfizer PFE:US $ 24094M 5117M
Regeneron Pharmaceuticals REGN:US $ 3452.8M 1685.7M
Regulus Therapeutics RGLS:US $ 0M 0M
Ultragenyx Pharmaceutical RARE:US $ 81.65M 5.33M